

REMARKS

Applicants respectfully request that the foregoing amendments be made prior to examination of the present application. The amendments are made to correct multiple dependencies and typographical errors and do not change the scope of the invention.

Respectfully submitted,

Date: January 29, 2003

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407

Facsimile: (202) 672-5399

By Eve L. Frank

Eve L. Frank
Registration No. 46,785

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION

Page 81, please replace the paragraph beginning on line 5 and ending on line 16 with the following:

100 μ l of the PCR solution containing **[5]10** μ l of 10 x PCR Gold Buffer II, 1.5mM $MgCl_2$, 0.08mM dNTPs (dATP, dGTP, dCTP, dTTP), 5 units of DNA-polymerase AmpliTag Gold (all by PERKIN ELMER) and each 2.5 [μ l] **pmole** of each synthesized oligonucleotide (12B5VH-1 to -4) was heated at 94⁰C of the initial temperature for 9 minutes, at 94⁰ C for 2 minutes at 55⁰C for 2 minutes and 72⁰C for 2 minutes. After repeating the cycle two times each 100 pmole of external primer 12B5VH-S and 12B5VH-A was added. The mixture was subjected to the cycle consisting of at 94⁰C for 30 seconds, at 55⁰C for 30 seconds and 72⁰C for 1 minute 35 times and heated at 72⁰ for further 5 minutes.

IN THE CLAIMS

3. (Amended) The modified antibody of claim 1 [or 2], wherein the linker comprises at least one amino acid.
4. The modified antibody of [any one of claims 1 to 3] **claim 1**, wherein the modified monoclonal antibody is a dimer of single chain Fv comprising an H chain V region and an L chain V region.
5. The modified antibody of [any one of claims 1 to 3] **claim 1**, wherein the modified antibody is a single chain polypeptide comprising two H chain V regions and two L chain V regions.
6. The modified antibody of [any one of claims 1 to 5] **claim 1**, wherein the modified antibody further comprises an amino acid sequence(s) for peptide purification.
7. The modified antibody of [any one of claims 1 to 6] **claim 1**, wherein the modified antibody has been purified.

8. The modified antibody of **[any one of claims 1 to 7] claim 1**, wherein H chain V region and/or L chain V region is humanized H chain V region and/or L chain V region.

9. (Amended) The modified antibody of **[any one of claims 1 to 8] claim 1**, wherein the cell surface molecule is a hormone receptor or a cytokine receptor.

11. (Amended)The modified antibody **[of any one of claims 1 to 10] claim 1**, wherein the agonist action is induction of apoptosis, induction of cell proliferation and induction of cell differentiation.

12. (Amended) The monoclonal antibody of **[any one of claims 1 to 11] claim 1**, wherein the L chain V region and the H chain V region are from the same monoclonal antibody.

13. (Amended) The monoclonal antibody of **[any one of claims 1 to 12] claim 1** which shows an improved agonist action compared with the original monoclonal antibody.

14. (Amended) A DNA which encodes the modified antibody of **[any one of claims 1 to 13] claim 1**.

15. (Amended) An animal cell which produces the modified antibody of **[any one of claims 1 to 13] claim 1**.

16. (Amended) A microorganism which produces the modified antibody of **[any one of claims 1 to 13] claim 1**.

17. (Amended) Use of the modified antibody of anyone of **[claims 1 to 13] claim 1** as an agonist.

22. (Amended) The method of claim 20 **[or 21]** wherein the substance which crosslinks the ligands is an antibody, an antibody fragment or a bivalent modified antibody.